Chemokine receptor antagonists and methods of use

Patent metadata

Field	Value
Publication number	US-9663537-B2
Application number	US-201514643773-A
Country	US
Kind code	B2
Filing date	Mar 10, 2015
Priority date	Nov 21, 2001
Publication date	May 30, 2017
Grant date	May 30, 2017

Abstract

Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by:

or physiologically acceptable salt thereof.

First claim

What is claimed:

1. A method for treating a disease associated with aberrant leukocyte recruitment, aberrant leukocyte activation or aberrant leukocyte recruitment and activation, comprising administering to a subject in need thereof an effective amount of a compound having the formula:

or a physiologically acceptable salt thereof, wherein:
n is one to four;
M is >CR 1 R 2 ;
R 1 is —OH;
R 2 is 4-halophenyl;
R 70 and R 71 are —H, and R 72 and R 73 are —CH 3 ; or
R 70 and R 71 are —CH 3 , and R 72 and R 73 are —H;
Z is

X 1 is —CH 2 O—;
Ring A is unsubstituted;
R 40 is selected from the group consisting of:

wherein the disease is selected from the group consisting of arthritis, atherosclerosis, arteriosclerosis, restenosis, ischemia/reperfusion injury, diabetes mellitus, psoriasis, multiple sclerosis, inflammatory bowel diseases, resection of a transplanted organ or tissue, graft versus host disease, allergy and asthma.

2. The method of claim 1 , wherein R 40 is

3. The method of claim 1 , wherein said 4-halophenyl is selected from the group consisting of 4-chlorophenyl, 4-bromophenyl and 4-fluorophenyl.

4. The method of claim 3 , wherein said 4-halophenyl is 4-chlorophenyl.

5. The method of claim 4 , wherein:
R 70 and R 71 are —H and R 72 and R 73 are —CH 3 ;
n is two; and
the compound has the structure:

6. The method of claim 5 , wherein R 40 is

7. The method of claim 1 , wherein said disease is multiple sclerosis.

8. The method of claim 1 , wherein said disease is arthritis, and said arthritis is rheumatoid arthritis.

Assignees

• Millennium Pharm Inc
• Kyowa Hakko Kirin Co Ltd

Inventors

• Luly Jay R
• Nakasato Yoshisuke
• Ohshima Etsuo
• Harriman Geraldine C B
• Carson Kenneth G
• Ghosh Shomir
• Elder Amy M
• Mattia Karen M

Classifications

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title